Assess whether the primary endpoint will survive FDA scrutiny (ffced1)

SITUATION The working file is 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week. Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways file.

DECISION Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; 505(b)(2) literature-to-product bridge table already has the discriminator after an inspector asking for batch records you cannot produce this week. 2. Keep Pause the pathway in force until 505(b)(2) literature-to-product bridge table is completed after an inspector asking for batch records you cannot produce this week for pharmacovigilance medical reviewer. 3. Treat 505(b)(2) literature-to-product bridge table as Escalate safety review because both readings appear after an inspector asking for batch records you cannot produce this week. 4. Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the decision the primary endpoint will turns on in 505(b)(2) literature-to-product bridge table.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 3. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim pharmacovigilance medical reviewer would keep. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against an inspector asking for batch records you cannot produce this week and write the one fact that would move the primary endpoint will for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after an inspector asking for batch records you cannot produce this week, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter.